Angiodynamics Inc ANGO
We take great care to ensure that the data presented and summarized in this overview for ANGIODYNAMICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANGO
View all-
Black Rock Inc. New York, NY4.6MShares$40.8 Million0.0% of portfolio
-
Systematic Financial Management LP Teaneck, NJ2.41MShares$21.4 Million0.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.29MShares$20.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.24MShares$19.8 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.35MShares$12 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.06MShares$9.36 Million0.01% of portfolio
-
Kent Lake Pr LLC Anasco, PR1MShares$8.86 Million3.09% of portfolio
-
Royce & Associates LP986KShares$8.74 Million0.07% of portfolio
-
Armistice Capital, LLC New York, NY962KShares$8.52 Million0.12% of portfolio
-
Geode Capital Management, LLC Boston, MA961KShares$8.51 Million0.0% of portfolio
Latest Institutional Activity in ANGO
Top Purchases
Top Sells
About ANGO
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Insider Transactions at ANGO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 02
2024
|
Lawrence T Weiss SVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,697
+50.0%
|
-
|
Oct 10
2024
|
Warren Nighan Jr SVP Quality and Regulatory |
BUY
Open market or private purchase
|
Direct |
100
+0.22%
|
$600
$6.08 P/Share
|
Oct 08
2024
|
Stephen A Trowbridge EVP and CFO |
BUY
Open market or private purchase
|
Direct |
1,700
+0.97%
|
$8,500
$5.86 P/Share
|
Oct 07
2024
|
Warren Nighan Jr SVP Quality and Regulatory |
BUY
Open market or private purchase
|
Direct |
768
+1.65%
|
$4,608
$6.09 P/Share
|
Oct 07
2024
|
James C Clemmer President and CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+2.85%
|
$120,000
$6.03 P/Share
|
Jul 21
2024
|
Stephen A Trowbridge EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
667
-0.4%
|
$4,669
$7.13 P/Share
|
Jul 21
2024
|
Warren Nighan Jr SVP Quality and Regulatory |
SELL
Payment of exercise price or tax liability
|
Direct |
277
-0.67%
|
$1,939
$7.13 P/Share
|
Jul 21
2024
|
James C Clemmer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,372
-0.53%
|
$23,604
$7.13 P/Share
|
Jul 21
2024
|
Laura Piccinini SVP International |
SELL
Payment of exercise price or tax liability
|
Direct |
413
-1.07%
|
$2,891
$7.13 P/Share
|
Jul 21
2024
|
Chad Thomas Campbell SVP/GM, Vascular Access |
SELL
Payment of exercise price or tax liability
|
Direct |
395
-0.62%
|
$2,765
$7.13 P/Share
|
Jul 20
2024
|
Stephen A Trowbridge EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
717
-0.43%
|
$5,019
$7.13 P/Share
|
Jul 20
2024
|
Warren Nighan Jr SVP Quality and Regulatory |
SELL
Payment of exercise price or tax liability
|
Direct |
251
-0.6%
|
$1,757
$7.13 P/Share
|
Jul 20
2024
|
James C Clemmer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,982
-0.47%
|
$20,874
$7.13 P/Share
|
Jul 20
2024
|
Laura Piccinini SVP International |
SELL
Payment of exercise price or tax liability
|
Direct |
616
-1.58%
|
$4,312
$7.13 P/Share
|
Jul 20
2024
|
Chad Thomas Campbell SVP/GM, Vascular Access |
SELL
Payment of exercise price or tax liability
|
Direct |
359
-0.56%
|
$2,513
$7.13 P/Share
|
Jul 19
2024
|
Stephen A Trowbridge EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,585
-1.49%
|
$18,095
$7.18 P/Share
|
Jul 19
2024
|
James C Clemmer President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,817
+0.59%
|
-
|
Jul 19
2024
|
Chad Thomas Campbell SVP/GM, Vascular Access |
SELL
Payment of exercise price or tax liability
|
Direct |
1,025
-1.57%
|
$7,175
$7.18 P/Share
|
Jul 19
2024
|
James C Clemmer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,307
-1.29%
|
$58,149
$7.18 P/Share
|
Jul 19
2024
|
Warren Nighan Jr SVP Quality and Regulatory |
SELL
Payment of exercise price or tax liability
|
Direct |
735
-1.74%
|
$5,145
$7.18 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 400K shares |
---|---|
Exercise of conversion of derivative security | 84.1K shares |
Open market or private purchase | 32.6K shares |
Payment of exercise price or tax liability | 64K shares |
---|